A Study to Assess an ATX Inhibitor (IOA-289) in Patients With Metastatic Pancreatic Cancer

Phase 1/2 Completed 16 enrolled iOnctura

NaSingle-groupOpen-labelTreatment

Summary

The objective of study IOA-289-102 is to evaluate the safety and tolerability of escalating doses of IOA-289 in patients with metastatic pancreatic cancer in combination with standard chemotherapy consisting of gemcitabine and nab-paclitaxel. Blood and tumour samples for PK and PD will be collected and assessments for determination of any clinical efficacy will be completed.

Timeline

Start: 2022-10-10
Primary completion: 2025-08-18
Completion: 2025-08-18

Outcome

Met primary endpoint

release “the Phase Ib study investigating oral autotaxin (ATX) inhibitor, cambritaxestat (IOA-289), has met the primary endpoint” ionctura.com ↗

Publications

Khasabova IA, Khasabov SG, Johns M, Juliette J, Zheng A, Morgan H, Flippen A, Allen K, Golovko MY, Golovko SA, Zhang W, Marti J, Cain D, Seybold VS, Simone DA. Exosome-associated lysophosphatidic acid signaling contributes to cancer pain. Pain. 2023 Dec 1;164(12):2684-2695. doi: 10.1097/j.pain.0000000000002967. Epub 2023 Jun 6.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CAMBRITAXESTAT	Small molecule	—	Oral
Background	Gemcitabine	Small molecule	—	Intravenous
Background	Nab-paclitaxel	Small molecule	—	Intravenous